BenzingaT3·4mo ago
SNGX Soligenix, Inc. Common Stock
XNAS
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
SNGX
—
—
Key stats
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNAS
- Market Cap
- $0.0B
- Employees
- 14
- List Date
- 1994-04-05
- CIK
- 0000812796
- Next Earnings
- 2026-11-06
- EPS Forecast
- ($0.12) (1 est.)
- Headquarters
- Princeton, NJ
- Homepage
- https://www.soligenix.com
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely: The Public Health Solutions business segment includes development programs for RiVax, a ricin toxin vaccine candidate, GX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease and various vaccine programs, including a program targeting filoviruses and CiVax; and The Specialized BioTherapeutics business segment…
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | 14.81% | -10.26% | -9.03% | -21.18% | -20.75% | -11.97% | -9.73% |
| Feb | 4.43% | 11.04% | -54.47% | 8.82% | 1.32% | -4.07% | -5.49% |
| Mar | -6.13% | 7.07% | -27.57% | -21.67% | -2.27% | 0.85% | -8.29% |
| Apr | -7.69% | -28.54% | -23.76% | -30.36% | -10.86% | -70.00% | -28.54% |
| May | -27.66% | 5.42% | -57.43% | -20.45% | -1.56% | 163.77% | 10.35% |
| Jun | 5.71% | 11.23% | -2.25% | -49.13% | -30.69% | -52.02% | -19.53% |
| Jul | -13.36% | 50.72% | -11.13% | 70.45% | 107.80% | -7.45% | 32.84% |
| Aug | 8.25% | -12.34% | -27.37% | -20.27% | 13.14% | 0.66% | -6.32% |
| Sep | 0.00% | -43.15% | 27.34% | 4.20% | -62.70% | -3.72% | -13.01% |
| Oct | -3.81% | 53.20% | -16.68% | -3.42% | 25.00% | -3.77%* | 8.42% |
| Nov | -12.41% | -17.52% | 100.12% | -13.21% | 8.16% | -- | 13.03% |
| Dec | -19.48% | -21.31% | 3.73% | -18.83% | -11.84% | -- | -13.55% |
| Total | -49.45% | -33.23% | -86.47% | -81.76% | -50.11% | -72.09% | -62.19% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $0.36
SMA 50: $0.37
SMA 200: $0.70
Current: $0.35
EMA 12: $0.36
EMA 26: $0.36
MACD: -0.0042 | Signal: 0.0015
BEARISH
ADX (14): 17.77
RANGE
+DI: 15.42
−DI: 19.12
Momentum Oscillators
RSI (14): 45.37
NEUTRAL
Stoch %K: 71.86
Stoch %D: 70.14
Williams %R: -48.16
Volume & Volatility
BB Upper: $0.37
BB Lower: $0.34
NEUTRAL
OBV: 933,386,326
Vol SMA 20: 134,454
Vol ROC: -23.26%
ATR: $0.02
True Range: $0.02
HV 20: 44.5%
HV 30: 40.2%
HV 60: 40.5%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-28T00:00:00 – 2026-10-26T00:00:00
AI Analysis
LLM Stock Analysis Report: SNGX
Executive Summary
Overall Assessment: BEARISH (Confidence Level: 6/10)
Key Drivers: High volatility, negative technical signals, lack of recent earnings data.
Primary Risks: Downside risk due to high beta and volatility, potential for further price decline if trend indicators continue to signal bearish momentum.
Investment Thesis: SNGX is a high-risk stock with limited fundamental support. The company's lack of recent earnings data and mixed technical signals create uncertainty around its future performance.
Recent News Sentiment Impact: Positive news sentiment (70%) from clinical trial pipeline acceleration and positive results from HyBryte comparative study, which may provide some upside potential.
Technical Analysis
Trend Direction: Short-term: BEARISH Medium-term: NEUTRAL Long-term: BEARISH
Support/Resistance Levels: Key levels to monitor:
- Resistance 1: $0.54 (SMA 20)
- Resistance 2: $0.72 (SMA 50)
- Support 1: $0.14 (Lower Bollinger Band)
Momentum Signals: RSI (14): 41.27 (neutral), indicating a potential pullback. MACD signal: -0.06 (bearish), suggesting further price decline.
Volume Analysis: Volume trends and institutional interest signals:
- Volume SMA 20: 21158804.92, indicating moderate volume activity
- On-Balance Volume (OBV): 1081631809.83, with a slight upward trend
News & Sentiment Analysis
Recent Headlines Summary: Positive news headlines on clinical trial pipeline acceleration and positive results from HyBryte comparative study.
Sentiment Assessment: Positive sentiment (70%) from recent news articles, which may provide some upside potential.
Catalyst Identification: Upcoming earnings data would be a significant catalyst. No earnings data available at this time.
Market Narrative: The technical signals indicate a bearish trend, while the positive news sentiment provides some counterbalance.
Risk & Volatility Assessment
Beta Interpretation: High risk relative to market (beta 1.91), indicating high volatility and potential for large price swings.
Volatility Regime: Current vs historical volatility levels: HIGH VOLATILITY - stock moves more than market.
Options Market Signals: No options data available.
Downside Protection: Support levels:
- Lower Bollinger Band: $0.14
- Previous low: $0.03
Market Context & Positioning
Sector Performance: Relative strength vs sector/market: MIXED - healthcare sector is strong, but SNGX's technical signals are bearish.
Institutional Activity: Volume patterns suggesting institutional interest:
- Moderate volume activity (Volume SMA 20)
- Slight upward trend in OBV
Correlation Analysis: How stock moves relative to market (R-squared interpretation): HIGH CORRELATION - stock is highly correlated with market movements.
Relative Valuation: Position within trading range: NEUTRAL - stock is not particularly undervalued or overvalued.
Key Levels & Action Items
Critical Price Levels: Support/resistance levels:
- Resistance 1: $0.54 (SMA 20)
- Resistance 2: $0.72 (SMA 50)
- Support 1: $0.14 (Lower Bollinger Band)
Breakout/Breakdown Levels: Technical levels that could trigger significant moves:
- Upper Bollinger Band: $0.93
- Lower Bollinger Band: $0.14
Time-Sensitive Catalysts: Earnings data, FDA approvals, product launches.
Risk Management: Stop-loss levels and position sizing considerations:
- Set stop-loss at $0.20 to limit potential losses.
- Consider reducing position size due to high volatility and bearish technical signals.
Generated
News
All SNGX news →
BenzingaT3·5mo ago
GlobeNewswire Inc.T3·5mo ago
GlobeNewswire Inc.T3·6mo ago
BenzingaT3·6mo ago
BenzingaT3·6mo ago
BenzingaT3·7mo ago
BenzingaT3·7mo ago
GlobeNewswire Inc.T3·7mo ago
BenzingaT3·7mo ago
Showing 1–10 of 50
Page 1 of 5
SNGX Options Activity & IV Rank
Loading options activity...
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
ATM — / Wing —
30 DTE / 10d
—
—
pts
EXTREME
ATM — / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
Risk Metrics
Beta: 1.9869
Alpha: -72.64%
Correlation: 0.1951
R-Squared: 3.8%
Stock Volatility: 129.8%
Market Volatility: 12.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
High volatility - stock moves more than market
Beta & Alpha Over Time
SNGX Institutional Ownership (13F)
Latest filings — 2026-09-30Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|
| # | Filer | Notional Value | % of Total | Period |
|---|
SNGX Insider Trading (Form 4)
Latest: 2026-10-13Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-10-13 | Robert J. Rubin | Director | Disp (D) | −632 opt | — | EDGAR | |
| 2026-10-13 | Anthony Gregg Lapointe | Director | Disp (D) | −632 opt | — | EDGAR | |
| 2026-10-13 | Jerome B Zeldis | Director | Disp (D) | −632 opt | — | EDGAR | |
| 2026-10-13 | Diane L. Parks | Director | Disp (D) | −566 opt | — | EDGAR | |
| 2026-10-13 | Oreola Donini | CSO | Disp (D) | −1,559 opt | — | EDGAR | |
| 2026-10-13 | Christopher J Schaber | CHAIRMAN, CEO AND PRESIDENT | Disp (D) | −2,832 opt | — | EDGAR | |
| 2026-10-13 | Jonathan L. Guarino | CFO | Disp (D) | −914 opt | — | EDGAR | |
| 2026-09-18 | Robert J. Rubin | Director | Grant (A) | +78,947 opt | — | EDGAR | |
| 2026-09-18 | Anthony Gregg Lapointe | Director | Grant (A) | +78,947 opt | — | EDGAR | |
| 2026-09-18 | Diane L. Parks | Director | Grant (A) | +78,947 opt | — | EDGAR | |
| 2026-09-18 | Jerome B Zeldis | Director | Grant (A) | +78,947 opt | — | EDGAR | |
| 2025-12-12 | Oreola Donini | CSO | Grant (A) | +100,000 opt | — | EDGAR | |
| 2025-12-12 | Richard Straube | CMO (Consulting) | Grant (A) | +10,000 opt | — | EDGAR | |
| 2025-12-12 | Jonathan L. Guarino | CFO | Grant (A) | +100,000 opt | — | EDGAR | |
| 2025-12-12 | Christopher J Schaber | CHAIRMAN, CEO AND PRESIDENT | Grant (A) | +200,000 opt | — | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
SNGX Insider Holdings
2 insiders · @ $0.35
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Christopher J Schaber | CHAIRMAN, CEO AND PRESIDENT | 15,511 | $5.4K | $34.0K | 10 | 2026-10-13 |
| 2 | Richard Straube | CMO (Consulting) | 33 | $12 | $4.0K | 5 | 2025-12-12 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
SNGX Board & Officers
As of SEC filings through Oct 13, 2026Directors 5
- Anthony Gregg Lapointe · since Mar 10, 2009
- Robert J. Rubin · since Oct 8, 2009
- Jerome B Zeldis · since Jun 22, 2011
- Christopher J Schaber · listed since Apr 2019
- Diane L. Parks · since Jul 8, 2019
Officers 4
- Christopher J Schaber · Chairman, CEO and President · listed since Sep 2010
- Richard Straube · Senior Vice President and CMO · listed since May 2022
- Jonathan L. Guarino · Chief Financial Officer · listed since Jan 2022
- Oreola Donini · Cso · listed since Dec 2020
Changes in the last 10 years (20)
| Jul 7, 2023 | The company announced the departure of Timothy R. Cote from the board in an SEC filing |
| May 3, 2023 | Timothy R. Cote became a director |
| May 18, 2022 | Richard Straube listed as Senior Vice President and CMO (previously CMO) in SEC filings |
| Jan 21, 2022 | Jonathan L. Guarino listed as Chief Financial Officer (previously Senior Vice President and CFO) in SEC filings |
| Dec 15, 2021 | Jonathan L. Guarino listed as Senior Vice President and CFO (previously Chief Financial Officer) in SEC filings |
| Dec 11, 2020 | Richard Straube listed as CMO (previously SVP and CMO) in SEC filings |
| Dec 11, 2020 | Oreola Donini listed as Cso (previously SVP and CSO) in SEC filings |
| Dec 11, 2020 | Jonathan L. Guarino listed as Chief Financial Officer (previously Senior Vice President and CFO) in SEC filings |
| Sep 9, 2019 | Jonathan L. Guarino became Senior Vice President and CFO |
| Jul 8, 2019 | Diane L. Parks became a director |
| Apr 22, 2019 | Christopher J Schaber first listed as a director in an SEC filing |
| Dec 14, 2018 | Christopher J Schaber no longer listed as a director in SEC filings |
| Jul 2, 2018 | Mark E. Pearson became a director |
| Jul 2, 2018 | Mark E. Pearson became a 10% owner |
| Dec 1, 2017 | SPA Essetifin reported in an SEC filing no longer being a 10% owner |
| Dec 1, 2017 | Paolo Cavazza reported in an SEC filing no longer being a 10% owner |
| Dec 1, 2017 | Leadiant Biosciences, Inc. reported in an SEC filing no longer being a 10% owner |
| May 8, 2017 | Randal J Kirk reported in an SEC filing no longer being a 10% owner |
| May 8, 2017 | Intrexon Corp reported in an SEC filing no longer being a 10% owner |
| Apr 4, 2017 | Richard Straube listed as SVP and CMO (previously Senior VP & CMO) in SEC filings |
Not reported recently (4)
- Mark E. Pearson · Last reported as a director in an SEC filing dated Sep 10, 2019
- Karen R Krumeich · Last reported as SVP and CFO in an SEC filing dated Dec 14, 2018
- Keith L Brownlie · Last reported as a director in an SEC filing dated Sep 28, 2018
- Marco Maria Brughera · Last reported as a director in an SEC filing dated Jun 12, 2017
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
ETF Holders
1 ETF hold SNGX
1 shown · $29.32K total exposure
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VXF Vanguard Extended Market ETF | Vanguard | 0.00% | $29,324 | — | 2026-09-30 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.